Brexucabtagene Autoleucel (Tecartus)

Abstract


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses brexucabtagene autoleucel (Tecartus) cell suspension in a patient-specific single-infusion bag for IV use at a target dose of 1 × 106 chimeric antigen receptor T-cells per kilogram.
 Indication: For the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.